Q-omics provides the consensus-scored IL36G profile across patient tissues and cancer cell-line models. IL36G expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, IL36G is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, IL36G protein abundance shows 12,901 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight MESO, and HNSC as cancer lineages where IL36G shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IL36G — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IL36G survival associations across molecular data types. IL36G RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IL36G RNA expression–survival associations across cancer types. High IL36G expression shows unfavorable associations in MESO, ACC, KIRC, KICH, STAD and LGG. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for IL36G RNA expression.
This table summarizes IL36G tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for IL36G. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IL36G shows higher tumor expression in HNSC, LUAD, LUSC, THCA, COAD and UCEC. The HNSC box plot shows higher IL36G RNA expression in tumor versus normal tissue (log2 FC = +1.885, t-test p < 0.001).
This table shows molecular features associated with IL36G in patient tissues and cancer cell lines. In patient samples, IL36G shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, IL36G RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and UPPER_AERODIGESTIVE_TRACT.
